Riskpilot← Back to searchSign inGet full accessDANCANN PHARMA A/S
A/SActiveCVR 39426005Rugvænget 5Manufacture of pharmaceutical preparations · NACE 2120Est. 20185 employeeshttps://dancann.com
Revenue 2024
DKK 0
EBITDA margin
—
+63% vs 2023
Equity ratio
91.5%
Financial strength
Net profit 2024
DKK -8,3M
+87% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK -4,9M | +63% |
| Net profit | DKK -8,3M | +87% |
| Total assets | DKK 16M | -10% |
| Equity | DKK 14,6M | +54% |
| Employees | 5 | — |
Legal name
DANCANN PHARMA A/S
CVR number
39426005
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
20. marts 2018
Share capital
DKK 3.991.101
Employees
5 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren og bestyrelsesformanden i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er fremstilling og udvikling af cannabinoid-baseret medicin samt handel med denne - herunder eksport og import - samt anden virksomhed og aktiviteter, der efter bestyrelsens skøn står i forbindelse hermed.
Address
Rugvænget 5
Phone
+4569160393
Email
INFO@DANCANN.COM
Website
https://dancann.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | -85 | -422 | -4.830 | 0 | 0 | 0 | 0 |
| Staff expenses | -70 | -1.146 | -947 | -7.091 | -7.496 | -8.109 | -4.774 |
| EBITDA | -156 | -1.567 | -5.776 | -13.864 | -15.071 | -13.408 | -4.922 |
| Depreciation & amort. | -0 | -8 | -94 | -624 | -955 | -45.945 | -750 |
| EBIT | -156 | -1.575 | -5.870 | -14.488 | -16.026 | -59.353 | -5.672 |
| Net financials | -4 | -12 | -116 | -751 | -2.417 | -2.996 | -2.674 |
| Profit before tax | -160 | -1.587 | -5.986 | -15.239 | -18.443 | -62.349 | -8.346 |
| Tax | -35 | -347 | -1.732 | -3.489 | -2.379 | -89 | -0 |
| Net profit | -125 | -1.240 | -4.255 | -11.750 | -16.064 | -62.260 | -8.346 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 58 | 733 | 49.549 | 68.102 | 73.276 | 17.710 | 15.974 |
| Equity | -125 | -1.365 | 44.326 | 53.370 | 62.793 | 9.506 | 14.620 |
| Long-term debt | 0 | 0 | 24 | 0 | 0 | 0 | 0 |
| Short-term debt | 183 | 2.098 | 3.862 | 13.758 | 10.483 | 8.204 | 1.354 |
| Total debt | 183 | 2.098 | 3.886 | 13.758 | 10.483 | 8.204 | 1.354 |
EBITDA margin
-492200000.0%
This company
15.8%
Market median
-3115189973% vs market
20182024
Equity ratio
91.5%
This company
38.2%
Market median
+140% vs market
20182024
Return on equity
-57.1%
This company
18.4%
Market median
-410% vs market
20182024
Net profit margin
-834600000.0%
This company
8.1%
Market median
-10303703804% vs market
20182024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182024
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-03-20 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PH Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Chairman | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 5.0% | 5.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2020 | |
Nips Isolering ApS | Company | 0.0% | 0.0% | 2019 |
VaVi Invest ApS | Company | 0.0% | 0.0% | 2019 |
HeRoed ApS | Company | 0.0% | 0.0% | 2019 |
XIGNOTUS CAPITAL ApS | Company | 5.0% | 5.0% | 2022 |
| Individual | 5.0% | 5.0% | 2019 | |
JBJensen ApS | Company | 0.0% | 0.0% | 2019 |
| Individual | 5.0% | 5.0% | 2021 | |
| Individual | 25.0% | 25.0% | 2023 | |
| Individual | 5.0% | 5.0% | 2020 | |
| Individual | 5.0% | 5.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of DANCANN PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Hauberg Søndergaard | Chief Executive Officer | 0 companies |
| Tue Østergaard | Board of Directors | 0 companies |
| Christian Carlsen | Deputy Chairman | 0 companies |
| Jes Lunde | Board of Directors | 0 companies |
| Per Wester | Board of Directors | 0 companies |
| Louise Bertelsen Forman | Board of Directors | 0 companies |
| Jeppe Krog Rasmussen | Board of Directors | 0 companies |
| Magnus Østergaard Dahlmann | Chairman | 0 companies |
| Carsten Trads | Chairman | 0 companies |
| Alexander Schoeneck | Board of Directors | 0 companies |